| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7052 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2003-02-28^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9b04b675a07784e8fbf75a19df1dbdc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10d3f7bb80b9a6bb681b0a3f52cfe056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9327f4e4b78e5eaf1aad18c2bff51138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db08e93699f53b558c00a2fb406388d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab3062e4ef05b653182fbbf9236e6a1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6630ac5cca73966f08054cea13bc312
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d0d72612027673f198d60eb9ba1e3b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_431d4f50ea43c667c7137d2aab5bc303 |
| publicationDate |
2003-10-31^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
UY-27692-A1 |
| titleOfInvention |
COMBINATION THERAPIES TO TREAT DEFICIENT CELLS IN METHYLTIOADENOSINE-PHOSPHORILASE. |
| abstract |
The present invention relates to combination therapies for treating cell proliferation disorders associated with methylthioadenosine phosphorylase ("MTAP") deficient cells in a mammalian animal. Combination therapies selectively destroy MTAP-deficient cells by administering an inhibitor of de novo inosinate synthesis and administering an anti-toxic agent, wherein de novo inosinate synthesis inhibitors are glycinamidaribonucleotide-formyltransferase inhibitors (GARFT ) and / or aminoinidazolcarboximidaribonuleotide-formyltransferase "(AICARFT"), and the anti-toxic agent is an analogue of an MTA precursor or a prodrug of an MTAP substrate. |
| priorityDate |
2002-03-04^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |